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Wilms tumour (WT), an embryonal kidney cancer, has been extensively
characterised for genetic and epigenetic alterations, but a proportion of
WTs still lack identifiable abnormalities. To uncover DNA methylation
changes critical for WT pathogenesis, we compared the epigenome of foetal
kidney with two WT cell lines, filtering our results to remove common
cancer-associated epigenetic changes and to enrich for genes involved in
early kidney development. This identified four hypermethylated genes, of
which ESRP2 (epithelial splicing regulatory protein 2) was the most
promising for further study. ESRP2 was commonly repressed by DNA
methylation in WT, and this occurred early in WT development (in
nephrogenic rests). ESRP2 expression was reactivated by DNA methyl-
transferase inhibition in WT cell lines. When ESRP2 was overexpressed in
WT cell lines, it inhibited cellular proliferation in vitro, and in vivo it sup-
pressed tumour growth of orthotopic xenografts in nude mice. RNA-seq of
the ESRP2-expressing WT cell lines identified several novel splicing targets.
We propose a model in which epigenetic inactivation of ESRP2 disrupts
the mesenchymal to epithelial transition in early kidney development to
generate WT.
1. Introduction
Wilms tumour (WT; nephroblastoma) is an embryonal
kidney cancer [1,2], which originates from foetal kidney
(FK), due to the failure of the mesenchymal to epithe-
lial transition (MET) that the metanephric blastema
undergoes during early nephrogenesis. Premalignant
lesions (nephrogenic rests; NRs) are often found as
microscopic lesions in the normal kidney (NK) adjacent
to WTs [3]. It is hypothesised that genetic and epige-
netic defects occur during renal development that block
MET, leading to the formation of NRs, some of which
progress to WT [1–3].
The molecular events underlying WT pathogenesis
involve an array of genetic and epigenetic defects [2].
The earliest genetic mutations in WT were found in
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the WT1 gene, which plays a critical role in regulating
MET during nephrogenesis [2]. The Wnt pathway is
also vital in renal development [2], and mutations in
Wnt pathway components including CTNNB1 [4,5]
and WTX (AMER1) [6] have also been found in WT.
Recent genome-wide sequencing studies have identified
mutations in microRNA-processing genes, such as
DROSHA, DICER and DGCR8, and mutations in
other renal developmental regulators, including SIX1,
SIX2 and SALL1 [7–12]. Most of these events show
no strong association with clinical outcome, but TP53
mutations are found in the rare anaplastic variant of
WT, which has a much poorer prognosis than other
subtypes [13].
Epigenetic alterations are also common in WT, espe-
cially at the 11p15 locus, where the frequent loss of
imprinting of the foetal growth factor gene IGF2 is
associated with DNA hypermethylation at H19 [14].
Other epigenetic alterations in WT include loss of
imprinting at 11p13 involving imprinted WT1 tran-
scripts [14,15], global hypomethylation [16], DNA
hypermethylation at individual tumour suppressor
genes such as RASSF1A [16–18], and long-range epige-
netic silencing of the PCDHG@ gene clusters [19].
Despite the identification of many loci with genetic
and/or epigenetic lesions in WT, a proportion of WTs
still lack identifiable driver defects, implying that addi-
tional novel genes are involved in WT pathogenesis
[7]. We previously used genome-wide DNA methyla-
tion analysis to identify novel epigenetic lesions in WT
[19], and here, we report further studies comparing
WT cell lines to foetal kidney. We have identified
novel differentially methylated genes, one of which is
the alternative splicing regulator ESRP2 (epithelial
splicing regulatory protein 2). ESRP2 is known to be
important in epithelial to mesenchymal transitions and
MET [20], suggesting that epigenetic deregulation of
MET may be an important factor in WT development.
We show that ESRP2 is frequently silenced by DNA
hypermethylation in WT and that it acts as a tumour
suppressor gene, regulating alternative splicing in novel
genes, some of which affect pathways known to be
important in kidney development.
2. Materials and methods
2.1. Ethical statement
WT samples were from Bristol Children’s hospital
(BCH), or from collaborators at the Royal Marsden
Hospital (RMH), as part of a UK collaboration. Sam-
ples were obtained with informed written consent (from
parent and/or legal guardian for children less than
18 years old) and with appropriate ethical approval
(E5797, Southwest – Central Bristol Research Ethics
Committee (UK)). All methods were performed in
accordance with the relevant regulations specified in the
UK Human Tissue Act 2004. The study methodologies
conformed to the standards set by the Declaration of
Helsinki. All animal experiments and procedures were
approved by the UK Home Office in accordance with
the Animals (Scientific Procedures) Act 1986. Mice were
maintained at the Biological Services Unit, University
of Exeter, UK. Housing and handling of mice have





WT cell lines Wit49 (a kind gift from Professor Her-
man Yeger, University of Toronto) [21] and 17.94
(established in our own laboratory; available from
DSMZ (German Collection of Microorganisms and
Cell Cultures), https://www.dsmz.de/dsmz) [22] were
grown in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% FBS, 100 UmL1 penicillin,
0.1 mgmL1 streptomycin, and 2 mM L-glutamine, at
37 °C in 5% CO2. WT cell line identity was confirmed
by short tandem repeat analysis (Fig. S1).
The V200 and E200L cell lines were derived by
transfecting Wit49 cells with the inducible expression
vector pBIG2r [23], either empty (V200) or containing
an ESRP2 cDNA insert (E200L). ESRP2 cDNA was
amplified by PCR from IMAGE clone 4810948, using
a forward primer containing a BamHI site and a
reverse primer containing an EcoRV site plus a FLAG
tag (Table S1), then ligated into BamHI/EcoRV-
digested pBIG2r (Fig. S2A). Transfected cells were
selected and maintained in 50 µgmL1 hygromycin B
(Santa Cruz Biotechnology). Only the ESRP2-
transfected Wit49 cells (E200L) expressed vector-
derived ESRP2 RNA (Fig. S2B). ESRP2 expression
was induced with 2-5 µgmL1 doxycycline (Dox,
Sigma), with maximum ESRP2 protein expression at
72 to 96 h postinduction (Fig. S2C).
2.3. Transient transfection
WT cell lines Wit49 and 17.94 were seeded into 6-well
plates (2 9 105 cellswell1) and transfected with 1 µg
plasmid expressing FLAG-tagged Esrp1 or Esrp2, or
empty vector (pIBX-C-FF-B-Esrp1/2 [24]), using
FuGENE 6 (Promega), according to the
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manufacturer’s instructions. Transfected cells were
selected with 2.5 µgmL1 blasticidin (Sigma) after
three days, and after 5 days, adherent cells were trypsi-
nised and counted.
2.4. Cell growth assays
For mass culture assays, cells were seeded into 6-well
plates (1 9 106 cellswell1) and treated with
2 µgmL1 doxycycline or DMSO vehicle control, with
medium changes every 3 days. Cells were trypsinised
and counted using a Countess Cell Counter and trypan
blue stain to exclude dead cells.
For colony assays, cells were seeded into 6-well
plates (2 9 105 cellswell1) and treated with
2 µgmL1 doxycycline or DMSO vehicle control.
Medium was changed every 3 days, and then at
14 days, cells were fixed, stained with methylene blue
and colonies counted manually.
To monitor proliferation in real time, cells were
seeded in 24-well plates (5 9 103 cellswell1) and
images were taken in four different fields per well
every 2 h (IncuCyte ZOOM live cell imaging system;
Essen BioScience) and phase confluence was calculated
as a surrogate for growth.
2.5. Transwell assay
Cells were pretreated for 4 days with 2 µgmL1 doxy-
cycline or control media and then seeded into Tran-
swell inserts (2 9 105 cellsinsert1 in FBS-free
DMEM; 8 µm pore, PET membrane; Falcon, 353093)
in a 6-well plate. Wells were filled with 1.7 mL 10%
FBS in DMEM to produce a chemotactic gradient.
After 24 h, inserts were washed and cells on underside
of membrane were fixed and stained with crystal violet
and counted manually using light microscopy.
2.6. Scratch assay
Cells were seeded into 24-well plates
(7.5 9 105 cellswell1) and treated with 2 µgmL1
doxycycline or DMSO vehicle control, prior to a scratch
being performed manually in the centre of each well.
Wells were washed with PBS to remove dead cells, con-
trol/doxycycline media replaced, and wells were analysed
at 24 and 48 h via Widefield microscopy, using ImageJ
software to determine percentage wound closure.
2.7. Cell Trace Violet (CTV) proliferation assay
1x106 cells were incubated for 20 min at 37 °C in the
dark in 1 mL of diluted CTV stain (Thermo Fisher;
C34571; prepared according to manufacturer’s instruc-
tions), then staining was quenched using 10% FBS in
DMEM, and cells were seeded into T12.5 flasks. Con-
trols were made by fixing 3x105 stained cells in 1%
paraformaldehyde and stored at 4 °C in the dark.
Seeded cells in T12.5 flasks were treated for 6 days
with 2 µgmL1 doxycycline or control media, and
intensity of CTV staining was analysed using a Novo-
Cyte Flow Cytometer and FLOWJO software.
2.8. 5-Aza-2’-deoxycytidine treatment
Cells were incubated in medium containing 2 µM 5-
aza-2’-deoxycytidine (Aza; Sigma, Gillingham, UK) or
drug solvent (DMSO) for up to 6 days, with a medium
change every 2 days.
2.9. Xenografting into nude mice
V200 and E200L cells were transduced with lentivirus
expressing firefly luciferase (Amsbio LVP326), and
transduced cells were selected with blasticidin, according
to the manufacturer’s protocol. For orthotopic kidney
implantation, male nude mice (2 months old; Charles
River) were anaesthetised using isoflurane, an incision
was performed in the left flank of the mice, the kidney
was exteriorised and 3 9 106 cells were injected. Mice
were imaged twice weekly (Xenogen IVIS), following
intraperitoneal injection with luciferin. When a biolumi-
nescent signal above background was detected (demon-
strating the establishment of tumour growth), mice were
injected intraperitoneally with doxycycline three times/
week (50 mgkg1 in 5% glucose). Mice were culled
either when tumours grew to the maximum allowed size
(10mm in diameter, according to the animal licence) or
after two months of imaging. The sample size was deter-
mined by power calculations using existing data from
similar experiments performed routinely in Dr Oltean’s
lab. More specifically, the sample size was obtained to
be able to see a significant difference (P > 0.05) for
tumour growth with a power value of 0.80 (> 80%). We
have used statistical principles and formulas available
on the following websites: www.nc3rs.org.uk; http://
www.statisticalsolutions.net/pss_calc.php. We have not
done randomisation in the animal experiments, and
there was no blinding of the investigator.
2.10. DNA extraction and methyl CpG
immunoprecipitation (MCIP)
DNA was extracted from WT cell lines with a DNeasy
kit (Qiagen, Manchester, UK). Human foetal kidney
DNA was obtained from BioChain. MCIP was
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performed as described previously [25] by co-
hybridising methylation-enriched DNA fractions with
input DNA onto a custom microarray (NimbleGen),
based on design 2006-04-28_HG18_Refseq_Promoter
(see GEO entry for further details). Statistical analyses
by ChIPMonk software (https://www.bioinformatics.
babraham.ac.uk/projects/chipmonk/) used windowed t-
tests to identify differentially methylated genes
(Table S2). MCIP data are accessible through GEO
Series accession number GSE153047: https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153047.
2.11. Pyrosequencing
DNA was purified by phenol/chloroform extraction,
bisulphite converted (EZ DNA Methylation Gold kit;
Zymo Research), amplified using a PyroMark PCR kit
(Qiagen) and pyrosequenced on a PyroMark Q96
instrument (Qiagen), using primers listed in Table S3.
2.12. RNA extraction, cDNA synthesis and RT-
PCR
Total RNA was extracted using TriReagent (Sigma)
and DNase treated with TURBO DNA-free (Ambion,
Gloucester, UK). Human foetal kidney RNA was
obtained from BioChain. cDNA was synthesised using
the Superscript IV RT-PCR system (Invitrogen,
Gloucester, UK). Gene-specific primers (Table S1) were
used for end-point PCR (HotStarTaq Plus DNA Poly-
merase; Qiagen), to detect inclusion or exclusion of
alternative exons, after electrophoresis on agarose gels
(1.5%). Quantitative real-time PCR (qPCR) using gene-
specific primers (Table S1) was performed using Quanti-
Nova SYBR Green Mix (Qiagen) on an MX3000P
real-time PCR machine (Stratagene), normalising the
amount of target gene to the endogenous level of TBP.
Human universal RNA (Agilent) was used as a refer-
ence to standardise results between qPCR batches.
2.13. Protein extraction and western blotting
Cells were washed with ice-cold PBS and lysed in cell
lysis buffer (Cell Signaling, London, UK), with complete
mini-inhibitors (Roche) for 10 min on ice, and then soni-
cated for 5 min (Diagenode, Bioruptor). 25 µg proteins
were separated on SDS/polyacrylamide gels and analysed
by western blotting. Primary antibodies were against
ESRP2 (rabbit, Abcam ab155227), FLAG (mouse,
Sigma F3165) and b-ACTIN (rabbit, Abcam AB8227),
followed by secondary HRP-labelled anti-rabbit IgG
(Sigma A6154) or anti-mouse IgG (Sigma A9044).
Chemiluminescence detection was with Lumiglo (KPL).
2.14. Immunofluorescence
Cells were grown on sterile glass slides, fixed for 30 min
at room temperature in 1% paraformaldehyde in PBS,
permeabilised for 10 min in 0.5% Triton X-100 in PBS
and finally rinsed in 50mM glycine in PBS. Fixed cells
were stained using a primary antibody against FLAG
(mouse, Sigma F3165) and secondary antibody against
mouse IgG (Alexa Fluor 488-labelled; Invitrogen) to
detect transfected ESRP2, together with Alexa Fluor
594-labelled phalloidin (Invitrogen) to detect actin.
Antibodies were diluted in PBS + 1% bovine serum
albumin, containing 0.1 µgmL1 DAPI to image
nuclei. Slides were mounted in Fluoroshield (Sigma)
and examined with a confocal microscope, acquiring
eight images at 1 µm spacing/field. Maximum intensity
projections were merged using ImageJ software (http://
imagej.nih.gov/ij/).
2.15. RNA sequencing (RNA-seq)
RNA was extracted from E200L cells 96 h after treat-
ment with 2 µgmL1 doxycycline, or control solvent
(DMSO), using an RNAeasy kit (Qiagen), then DNase
treated, and quality confirmed using an Agilent
ScreenTape RNA assay. Two biological replicates were
used for RNA-seq (i.e. four samples total). Sequencing
libraries were prepared from total RNA (500 ng) using
the TruSeq Stranded mRNA Library Preparation Kit
(Illumina, Inc., Cambridge, UK) and uniquely bar-
coded adapters (RNA LT adapters, Illumina, Inc).
Libraries were pooled equimolarly for sequencing,
which was carried out on the NextSeq500 instrument
(Illumina, Inc.) using the NextSeq High Output v2
150-cycle kit (Illumina, Inc.). Approximately 300 mil-
lion paired reads (passing filter, PF) were obtained,
divided between the four experimental samples. Next-
Seq Control Software version 2.0.0 and RTA v2.4.6
were used for instrument control and primary analysis,
respectively. Reads from the four samples were
mapped to the human genome (hg19) using the new
Tuxedo Suite of programs (HISAT2, StringTie, Ball-
gown; https://www.ncbi.nlm.nih.gov/pubmed/?term=
27560171). To identify RNA splicing alterations, the
four BAM files generated by HISAT2 were used as
input for rMATS ([26] http://rnaseq-mats.sourceforge.
net/user_guide.htm). Bam files were viewed in the Inte-
grative Genomics Viewer (http://software.
broadinstitute.org/software/igv/) to produce Sashimi
plots of alternative splicing. RNA-seq data are accessi-
ble through GEO Series accession number
GSE154496: https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE154496.
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2.16. Statistical analysis
Comparisons of two datasets were performed using
Student’s t-test or a Mann–Whitney U-test, depending
on whether the data met the normal distribution. A
comparison of three or more groups was performed
using one-way analysis of variance (ANOVA) with
Dunnett’s post-test or using Tukey’s pairwise test. The
Chipmonk software used for MCIP analysis and the
rMATS software used for RNA-seq analysis use Ben-
jamini and Hochberg FDR correction for multiple
testing. For smaller numbers of samples, Bonferroni
correction was used for multiple testing. Numbers of
samples quoted in figure legends (n) refer to biological
replicates. P < 0.05 was considered to indicate a statis-
tically significant difference.
3. Results
3.1. Genome-wide DNA methylation analysis
We used MCIP to identify 225 genes that were hyper-
methylated in two WT cell lines compared with foetal
kidney (Fig. 1A and Table S2). Gene ontology analy-
sis showed that these genes were particularly involved
in chromatin organisation, developmental processes
and transcriptional regulation (Fig. 1B and
Table S4). To distinguish genes that were methylated
specifically in WT, two filters were applied: (a) genes
were removed that are polycomb repressive complex
marked in embryonic stem cells, since such genes are
predisposed to DNA methylation in a wide range of
human cancers [27–29] and therefore might not be
WT-specific; (b) positive selection was applied for
genes that are upregulated in early nephrogenesis,
since their inactivation could induce the MET block
that is critical for WT development [2]. Using these
criteria, four candidate genes were pinpointed:
CHST2, KIT, PTTG1IP and ESRP2 (also known as
RBM35B) (Fig. 1A and Table S2), of which ESRP2
was the most consistently methylated in WT
(Fig. 1C).
ESRP2 was particularly attractive for further study,
because of its known involvement in epithelial to mes-
enchymal transitions in cancer [30]. Support for a role
in WT came from examination of the ESRP2 target
ENAH. ESRP2 induces inclusion of the epithelial-
specific exon 11a in ENAH RNA transcripts [24].
Using RT-PCR, less exon 11A was found expressed in
WTs compared with normal kidney (NK) and foetal
kidney (FK), consistent with downregulation of
ESRP2 in WT (Fig. 1D). We therefore went onto
examine DNA methylation and expression of ESRP2
in two large cohorts of WTs using pyrosequencing
(Figs. S3 and S4).
3.2. DNA methylation of ESRP2 in Wilms tumour
The first cohort of WTs from Bristol Children’s
Hospital (BCH) consisted of tumour samples of all
stages, obtained at surgical resection, prechemother-
apy. 72% of these WTs were hypermethylated at the
ESRP2 (DNA methylation > 25%) compared with
normal tissue (NT) (Fig. 2A and Fig. S4A). The sec-
ond cohort from the Royal Marsden Hospital
(RMH) were from stages 1 to 3, taken at surgical
resection, postchemotherapy. In this different cohort,
78% of WTs were hypermethylated (Fig. 2B and
Fig. S4C). ESRP1 DNA methylation was also tested
in the RMH cohort and found to be very low (< 2%)
in NT and WT, and not significantly different
(Fig. 2B). Additional independent DNA methylation
data were extracted for the ESRP1 and ESRP2 pro-
moters from the data set GSE59157, which showed
hypermethylation of ESRP2 in WTs, with much
lower methylation of ESRP1, that was only margin-
ally different between NT and WT (Fig. 2C). Thus,
ESRP2 DNA was hypermethylated in three indepen-
dent cohorts of WTs, but the ESRP2 paralog ESRP1
was not hypermethylated.
There was no significant association between tumour
stage and ESRP2 DNA methylation (Fig. S5A, B),
nor between ESRP2 methylation and survival
(Fig. S6), nor between tumour histology and ESRP2
methylation (Fig. S7A, C).
ESRP2 is located on chromosome 16q22, a chromo-
somal region showing frequent loss of heterozygosity
(LOH) in WT [31]. No difference was observed in the
ESRP2 methylation in WTs with or without 16q LOH
(Fig. S5C).
Most WTs are thought to develop via premalignant
lesions (NRs) [3]. To characterise the phase of WT
development at which ESRP2 DNA methylation
occurs, it was assayed in two sets of matched NK, NR
and WT. ESRP2 was found to be at a similar level of
hypermethylation in NRs and matched WTs compared
with NKs (Fig. 2D). In contrast, RASSF1A, a tumour
suppressor gene frequently hypermethylated in WT
[18], was not hypermethylated in NRs (Fig. 2D), as
previously reported [16]. Methylation values were also
extracted for NRs from data set GSE59157, and simi-
larly, ESRP2 was significantly more methylated in
both NR and WT compared with NK (Fig. 2E), but
RASSF1A was only hypermethylated in WTs and not
NRs compared with NK (Fig. 2E).
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To investigate whether epigenetic changes, including
ESRP2 hypermethylation, are associated with other
clinical and molecular features, the BCH cohort of
WTs were grouped by hierarchical clustering of DNA
methylation values at four loci: ESRP2, the WT1 anti-
sense regulatory region [15], H19 [14] and RASSF1A
[18] (Fig. S8 and Table S5). Interestingly, of the 22
WTs studied for WT1 mutations, all six WT1-mutant
WTs were in the same cluster (group 3), whereas ten
of the WT1 wild-type WTs were in group 1 or 2 and
six in group 3 (P = 0.015, Fisher exact test). This
difference in epigenetic profiles between WT1-mutant
and wild-type WTs is supported by similar findings in
a recent comprehensive characterisation of molecular
defects in WT [7].
ESRP2 DNA hypermethylation was also observed
in 10 of 16 (63%) non-WT childhood renal tumours
(Fig. S9A), especially in clear cell sarcomas of the kid-
ney and in rhabdoid tumours. In data sets GSE73187
and GSE4487, ESRP2 was also found to be hyperme-
thylated in clear cell sarcomas (Figs S9B, C) and rhab-
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Fig. 1. Identification of ESRP2 as a candidate hypermethylated gene. (A) Venn diagram showing filtering of the 225 methylated genes that
were identified by methyl CpG immunoprecipitation (MCIP), firstly by negative selection for genes that are polycomb repressive complex
(PRC) marked in embryonic stem cells and secondly by positive selection for genes that are upregulated in the renal vesicle during kidney
development. The full list of methylated genes and filtered lists are shown in Table S2. dev., development. (B) Gene Ontology analysis of
the 225 methylated genes. Only categories with a fold enrichment > 3 are shown; Table S4 for full results. (C) Bar chart of CHST2, KIT,
PTTG1IP and ESRP2 DNA methylation. Controls (Blank, Me 0% (unmethylated DNA control), Me 100% (fully methylated DNA control)), Cell
lines (Wilms tumour cell lines, n = 2), FK (foetal kidney, n = 4), NK (normal kidney, n = 2) and Wilms tumours (n = 15). DNA methylation
was assayed by pyrosequencing; Table S3 for pyrosequencing primers. (D) Alternative splicing of ENAH exon 11A was analysed by RT-PCR
followed by agarose gel electrophoresis in 2 WT cell lines (Wit49 and 17.94), FK, NK and 4 WTs. Representative of n = 3.
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TCGA data showed DNA methylation changes in
ESRP2 in several adult cancers, including hypermethy-
lation in two adult kidney cancers (renal clear cell car-
cinoma and renal papillary cell carcinoma; Fig. S9D).
This suggests that epigenetic inactivation of ESRP2
may be involved in the pathogenesis of several types
of renal tumours in adults and children, not just in
WT.
3.3. Expression of ESRP2 in Wilms tumour
In the BCH cohort, expression of ESRP2 in WT was
very low compared with NT (Fig. 3A and Fig. S4B)
and hypermethylation was associated with reduced
expression of ESRP2 (Fig. 3B). In the RMH cohort,
the expression of ESRP2 was also reduced in WT
compared with NT (Fig. 3C and Fig. S4D), but
ESRP1 expression was not significantly different
(Fig. 3C). In data set GSE2712, ESRP2 expression
was lower in WT compared with NT, but ESRP1
expression did not differ significantly (Fig. 3D). Like
methylation results, there was no relationship between
ESRP2 expression and tumour histology (Fig. S7B, D,
E). These results showed that ESRP2 but not ESRP1
expression was reduced in WTs compared with NT
and that reduced expression of ESRP2 was associated
with hypermethylation. When the two WT cell lines
were treated with the DNA methylation inhibitor 5-
aza-2’-deoxycytidine (Aza), there was a 5- to 10-fold
increase in ESRP2 RNA expression (Fig. 3E), suggest-
ing a mechanistic link between ESRP2 methylation
and gene expression.
3.4. Biological function of ESRP2 in vitro
The results described above suggested that ESRP2
may have an important functional role in the develop-
ment of WT. To carry out functional analyses, we ini-
tially used transient transfection to constitutively
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Fig. 2. ESRP2 is hypermethylated in Wilms tumours and nephrogenic rests. (A) Dot-boxplot of ESRP2 DNA methylation in the BCH cohort.
NT (normal tissue) n = 8 (4 NK (normal kidney) and 4 FK (foetal kidney), WT (Wilms tumour) n = 65, P value from t-test. (B) Dot-boxplot of
ESRP2 and ESRP1 DNA methylation in the RMH cohort. ESRP2: NT n = 18 (all NK), WT n = 73; ESRP1: NT n = 15 (all NK), WT n = 69, P
values from t-test. (C) Dot-boxplot of ESRP2 and ESRP1 DNA methylation in dataset GSE59157. NT n = 36 (all NK), WT n = 37, P values
from t-test. (D) RASSF1A and ESRP2 methylation in nephrogenic rests in the BCH cohort. Two sets of matched NK, NR (nephrogenic rest)
and WT are shown. (E) Dot-boxplot of RASSF1A and ESRP2 methylation in nephrogenic rests in the GSE59157 data set. 17 sets of matched
NK, NR and WT are shown for RASSF1A methylation and 13 sets for ESRP2 methylation, from individuals where the WT was hypermethy-
lated compared with the matched NK. P values from Tukey’s pairwise test. DNA methylation was assayed by pyrosequencing in A to D and
by Illumina Human Methylation 450 bead arrays in E.
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Wit49. Overexpression of ESRP2, but not of ESRP1,
produced strong growth inhibition in both cell lines
(Fig. S10). Due to the strong growth inhibition by
ESRP2, we were unable to establish stable cell lines
using these constitutively active expression vectors. We
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Fig. 3. ESRP2 expression is repressed in Wilms tumour and regulated by DNA methylation. (A) Dot-boxplot of ESRP2 RNA expression
relative to FK (foetal kidney) in the BCH cohort. NT (normal tissue) n = 6 (3 NK (normal kidney) and 3 FK), WT (Wilms tumour) n = 32, P
value from t-test. (B) Dot-boxplot of ESRP2 expression in hypomethylated versus hypermethylated samples in the BCH. Hypomethylated
n = 14 (ESRP2 methylation< 25%, Hypo), hypermethylated n = 24 (ESRP2 methylation > 25%, hyper), P value from t-test. (C) Dot-boxplot
of ESRP2 and ESRP1 RNA expression relative to NT in the RMH cohort. ESRP2: NT n = 12 (all NK), WT n = 51; ESRP1: NT n = 9 (all NK),
WT n = 33, P values from t-tests. (D) Dot-boxplot of ESRP2 and ESRP1 RNA expression in the GSE2712 data set. NT n = 3 (all FK), WT
n = 18, P values from t-tests. (E) 17.94 and Wit49 WT cell lines were treated with 2 µM Aza (5-aza-2’-deoxycytidine) for six days. ESRP2
RNA levels expressed relative to untreated cells. Results are mean  SD of n = 3, P values from paired t-tests. RNA expression was mea-
sured by real-time qPCR, normalised to endogenous levels of TBP in A, B, C and E, and by Affymetrix Human Genome U133A arrays in D.
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inducible ESRP2 expression vector (Fig. S2). Unfortu-
nately, we were unable to establish a stable cell line
from 17.94, but the WT cell line Wit49 was success-
fully transfected, producing the E200L cell line (V200
was the control cell line transfected with empty vec-
tor). E200L showed strong doxycycline-induced
expression of ESRP2 RNA (Fig. 4A) and protein
(Fig. 4B), with the expected nuclear localisation of
ESRP2 protein (Fig. 4D). Induction of ESRP2 drove
the splicing of the known target gene ENAH [24]
towards its epithelial splice form (+exon 11a; Fig. 4C),
demonstrating that the construct produced biologically
active ESRP2 in a WT cell line. There was slight leaki-
ness from the expression vector, with more ESRP2
RNA detected in uninduced E200L cells compared
with V200 cells (Fig. 4A), which probably explains the
increased level of ENAH exon 11a in uninduced
E200L cells compared with V200 cells (Fig. 4C).
Overexpression of ESRP2 was associated with an
apparent redistribution of actin filaments towards the
cell periphery (Fig. 4D), compared to a more cytoplas-
mic distribution of actin stress fibres in uninduced cells
(Fig. 4D), as reported in other systems [32,33].
ESRP2 overexpression caused decreased colony-
forming efficiency (Fig. 4E), as well as reduced growth
rate in mass cultures (Fig. S11). Real-time analysis of
cell density showed a slower cell proliferation rate in
the doxycycline-induced E200L cells (Fig. 4F), associ-
ated with a small but significant decrease in the rate of
cell division (Fig. 4G, H). Cell invasion (Fig. S12A)
and cell motility (Fig. S12B) showed no changes upon
induction of ESRP2 expression.
3.5. Xenograft assays of ESRP2 function in vivo
We used orthotopic xenografts of the Wit49-derived
cell lines, under the kidney capsule of nude mice [34]
(Fig. 5), to examine the effect of ESRP2 expression
in vivo. After treatment with doxycycline, tumours
produced by V200 cells continued to proliferate,
whilst tumours produced by E200L cells stopped
growing, or regressed (Fig. 5A and Fig. S13A, B).
V200 cells produced large tumours in four of five
mice, but only one mouse out of five injected with
E200L cells (1E-L) produced a large tumour (Fig. 5B
and Fig. S13C). Western blotting of excised tumours
demonstrated that doxycycline treatment had induced
high-level ESRP2 expression in all E200L tumours,
with the notable exception of 1E-L (where the tumour
grew larger) and V200-induced tumours (Fig. 5C).
This therefore demonstrated a strong correlation
between ESRP2 expression and suppression of
tumour growth.
3.6. RNA-seq analysis of alternative splicing in
Wilms tumour cell lines
In biological duplicates, we carried out RNA-seq on
E200L cells that were doxycycline-induced (ESRP2-
expressing) or uninduced (non-expressing), obtaining
between 70 and 80 million paired-end reads per sam-
ple. These reads were mapped onto the human gen-
ome, examined for differential gene expression and
used in rMATS software [26] to identify alternative
splicing events.
Very few transcripts, apart from ESRP2, showed
significant changes in RNA expression (P < 0.05, fold
change > 2) when ESRP2 expression was induced
(Fig. 6A, B). Interestingly, one induced gene was
GRHL1, and grainyhead-like transcription factors are
important in both kidney development and MET [35],
making them good candidates for an involvement in
WT. However, we found no difference in expression of
GRHL1 between NT and WT (Fig. S14), which does
not support a role for altered GRHL1 expression in
WT pathogenesis.
In contrast to the lack of altered gene transcription,
ESRP2 induction was associated with over 900 splicing
events involving over 700 genes, with significant
changes (false discovery rate, FDR < 0.05) in skipped
exons, mutually exclusive exons and retained introns
(Fig. 6C, Table S6, S7, and S8). The genes involved
were particularly enriched for biological processes con-
cerned with vesicular and intracellular transport
(Table S9). Although we found many ESRP target
genes in common with other reports [36,37], we also
identified over 600 novel target genes (Fig. 6D). Com-
parison with a recent study of MET-associated alter-
native splicing changes during kidney development [38]
also revealed overlap with some of our target genes
(Fig. 6E). Interestingly, the two lists of genes identified
as overlapping our ESRP2 targets, included five genes
(33–36%) in common (CTNND1, CTTN, FLNB,
MAP3K7 and MPRIP; shown in bold in Fig. 6D, E),
emphasising the importance of ESRP-regulated alter-
native splicing in kidney development.
We validated a selection of putative targets by speci-
fic RT-PCR assays, to examine exon inclusion upon
ESRP2 induction. We successfully validated several
previously identified targets; CD44, ENAH, FGFR2,
SCRIB and SLK (Fig. S15), as well as the novel tar-
gets LEF1, NPHP1 and RAC1 (Fig. 6F, G, H). How-
ever, some putative target genes showed no altered
splicing after ESRP2 induction (Fig. S16 and
Table S10).
To investigate the possible role of ESRP2 target
genes in WT pathogenesis, we examined alternative
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splicing of 12 genes (seven novel and five previously
described) in FK, NK and WT (Fig. 7 and Fig. S17).
Five genes (42%) showed significant changes in the
degree of alternative splicing between normal tissues
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4. Discussion
This is the first demonstration of ESRP2 repression
caused by DNA hypermethylation in WT, which
implicates RNA splicing alterations as an important
pathogenic factor in WT development. Investigation of
matched sets of NK, NR and WT (Fig. 2D, E)
suggested that inactivation of ESRP2 by DNA methy-
lation occurs at an early stage in kidney development,
prior to NR formation. We propose that ESRP2 is
essential for the differentiation of the metanephric
blastema into nephrons (Fig. 8B) and that loss of
ESRP2 expression causes a differentiation block, initi-







































































































Fig. 5. Tumorigenicity of ESRP2-expressing WT cells. Orthotopic xenografts of V200 and E200L cells were produced by injecting cells under
the kidney capsule of nude mice (n = 5 for each cell line). When a bioluminescent signal was detected above background (incipient growth
of tumours), mice were injected intraperitoneally with doxycycline (Dox) three times per week, as described in Materials and Methods. (A)
Time course of tumour growth as assayed by in vivo bioluminescence in V200 (left) and E200L (right) xenografts. Plots show tumour signals
days after doxycycline induction (i.e. first doxycycline injection = day zero) for each individual mouse. Plot of the average of the
bioluminescence traces is shown in Fig. S13A. (B) Tumours excised from mice (no tumour was excisable in mouse 1B-0 at day 63,
therefore only four E200L tumours are shown). Full details of tumour size and weight are shown in Fig. S13C. (C) Western blot of ESRP2
protein expression in excised tumours.
Fig. 4. Inducible expression of ESRP2 in a Wilms tumour cell line. V200 is a control WT cell line (transfected with empty vector), and E200L
is a WT cell line expressing doxycycline-inducible ESRP2 (Materials and Methods). (A) ESRP2 RNA expression assayed by qPCR, normalised
to endogenous levels of TBP, in V200 and E200L cells after 72-h doxycycline (Dox) induction, shown as fold induction relative to uninduced
V200 cells. Results are mean SD of n = 3, P value from paired t-test. (B) ESRP2 protein assayed by western blotting in V200 and E200L
cells after 72-h doxycycline induction. Anti-ESRP2 detected total ESRP2 protein, anti-FLAG detected vector-derived ESRP2 and anti-ACTIN
was used as a loading control. Representative of n = 3. (C) Alternative splicing of ENAH exon 11A was analysed by RT-PCR followed by
agarose gel electrophoresis to detect different sized amplicons, in V200 and E200L cells after 72-h doxycycline induction. Representative of
n = 3. (D) Immunofluorescence of E200L cells, stained for FLAG-tagged ESRP2 (green) and ACTIN (red) in the left-hand panels, and for
nuclear DNA with DAPI (blue) in the right-hand panels, after 72-h doxycycline induction (+Dox), or uninduced (-Dox). Scale bars = 50 µm. (E)
Colony-forming assay of induced (doxycycline-treated) and uninduced V200 and E200L cells, shown as fold colony numbers compared to
uninduced controls after 14 days. Results are mean  SD of n = 3, P values from paired t-test. (F) Cell confluence assay (by IncuCyte),
showing growth of induced (doxycycline-treated) and uninduced V200 and E200L cells. Results are mean  SD of n = 6, P value at 162 h
from paired t-test. Representative of n = 3. (G) H: Cell trace violet (CTV) proliferation assay of induced (doxycycline-treated) and uninduced
V200 and E200L cells. (G) CTV staining of triplicates of induced and uninduced cells showing median fluorescence intensity histograms at
6 days of treatment. Red peaks are controls representing staining of cells at day zero. (H) Dot-boxplot of quantitation of staining at 6 days
(n = 3). P values from paired t-tests of log-transformed values.
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Fig. 6. RNA-seq analysis identifies ESRP2 targets in a WT cell line. RNA-seq was performed on E200L cells with or without 96 h of
doxycycline induction (to induce high-level ESRP2 expression). (A) Volcano plot of P value versus fold induction of transcripts in ESRP2-
expressing E200L cells compared with non-expressing cells. Genes induced > 2-fold with P < 0.05 are indicated in red, and ESRP2 is
labelled. (B) List of genes in A that were induced > 2-fold with P < 0.05. (C) Number of altered splicing events and affected genes induced
by ESRP2 expression. SE; skipped exons, MXE; mutually exclusive exons; RI, retained introns. Tables S6 to S8 for full details. (D) Venn
diagram comparing genes identified in this study (SE + MXE + RI) with two other RNA-seq analyses of ESRP-induced splicing changes
[36,37]. (E) Venn diagram comparing genes identified in this study (SE + MXE + RI) with an RNA-seq analysis of MET-associated splicing
changes in the developing kidney [38]. (F, G and H) Alternative splicing of novel targets LEF1 (F), NPHP1 (G) and RAC1 (H). Left-hand
panels: Sashimi plots of RNA-seq data from E500L cells uninduced (-Dox) or induced to express ESRP2 (+Dox). Right-hand panels: Agarose
gels of RT-PCRs of amplicons spanning alternatively spliced exons (Table S1 for primers), in V200 and E200L cells, either uninduced, or
doxycycline-induced to produce high-level ESRP2 expression in E200L cells.
12 Molecular Oncology (2021) ª 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
ESRP2 methylation in Wilms tumour D. Legge et al.
epigenetic defects to produce WT (Fig. 8C). Support
for this model comes from studies showing that the
Esrp paralogs are expressed in the developing kidney
[39], with increased expression of Esrp 1 and 2 when
renal precursors undergo epithelial differentiation [38],
and that knockout of Esrp genes in mice decreases
kidney volume, due to a lack of nephrons [40].
Inactivation of ESRP2 as an early premalignant
event in WT development probably explains why we
found no association with clinical features (Figs S5
and S6). It also explains why we found no association
between ESRP2 methylation and LOH at 16q
(Fig. S5C), where the ESRP2 gene is located, because
we have previously demonstrated that 16q LOH occurs
after NR formation [14], that is after ESPR2 hyperme-
thylation.
We have shown that ESRP1, though an ESRP2 par-
alogue, is not repressed by hypermethylation in WTs
(Fig. 2B, C and Fig. 3C, D). This implies that ESRP1
and ESRP2 may have different biological functions
and are regulated differently in some instances, as
recently reported in prostate cancer, where ESRP2 but
not ESRP1 is regulated by androgens [41].
Splicing alterations are frequent in human cancers
[42], including ESRP-induced changes in breast cancer
[43,33], prostate cancer [44,41], renal cell carcinoma
[45] and colorectal cancer [46]. Most studies have
reported expression changes without finding underlying
genetic or epigenetic defects in the ESRP genes them-
selves [46,43,45,41,33]. However, there are reports of
genetic defects in ESRP genes in human cancers,
specifically, microsatellite indels [47] or duplications
[44] of ESRP1. In addition, there are reports of DNA
methylation changes in ESRP1 in prostate cancer [48]
and of ESRP2 in breast cancer [49], and our examina-
tion of TCGA data (Fig. S9D) demonstrated ESRP2
methylation changes in several other adult cancer
types. Thus, our results add to a growing body of evi-
dence that ESRP genes can be either genetically or
epigenetically deregulated in a wide range of human
cancers.
Our functional studies suggested that the main bio-
logical effect of ESRP2 is to regulate cell proliferation
by slowing cell division (Fig. 4E–H and Fig. S11).
Whilst we observed some actin cytoskeleton rearrange-
ment (Fig. 4D), we did not observe significant expres-
sion changes in classical epithelial marker genes
(Fig. 6A, B), nor any changes in cell motility or inva-
sion (Fig. S12), unlike what occurs when ESRP
expression is modulated in adult human cancer cell
lines [32,33,30]. Coupled with our xenograft experi-
ments that identify ESRP2 as a bona fide tumour sup-
pressor gene (Fig. 5), these results suggest that the
tumour suppressor activity of ESRP2 in WT cell lines
occurs mainly by altering cell growth properties, rather
than by affecting cellular differentiation.
Mechanistically, our RNA-seq results demonstrated
that ESRP2 modulated the splicing of a diverse range
of genes, including both well-established and novel tar-
gets (Fig. 6 and Tables S6 to S8). A subset of these
genes showed reduced expression of their epithelial
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Fig. 7. Alternative splicing of ESRP2 target genes in Wilms
tumour. (A to E) Left-hand panels: Representative agarose gels of
RT-PCRs of amplicons spanning the alternatively spliced exons
(Table S1 for primers), from FK (foetal kidney), NK (normal kidney)
and WT (Wilms tumour). FGFR2 exon IIIb was detected by
restriction digest with AvaI [24]. Right-hand panels: Dot-boxplots
showing per cent splice inclusion (PSI) in NT (normal tissue) and
WT. P values from t-test. ENAH (A), NT n = 11 (4 FK and 7 NK),
WT n = 17; FGFR2 (B), NT n = 5 (3 FK and 2 NK), WT n = 12;
LEF1 (C), NT n = 8 (5 FK and 3 NK), WT n = 17; SCRIB (D), NT
n = 5 (2 FK and 3 NK), WT n = 9; SLK (E), NT n = 5 (2 FK and 3
NK), WT n = 8.
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hypermethylation-induced downregulation of ESRP2
in WT (Fig 2 and Fig. 3). Interestingly, of the 728
genes that we identified as having their splicing modu-
lated by ESRP2 (Fig. 6), only 62 (9%) are WT1
DNA-binding targets [50], whereas 244 (34%) are
WT1 RNA-binding targets [51] (Fig. 8A). The WT1
RNA-binding targets include all five of the ESRP2-
regulated genes that we found in common between our
results and two other RNA-seq studies (Fig. 6D, E).
This suggests that WT1 and ESRP2 are involved in
the post-transcriptional regulation of a similar set of
genes during renal development. Since ESRP2 hyper-
methylation is an early event, like WT1 mutation
[52,53], this suggests that ESRP2 hypermethylation
may be another important early event in WT
development, which contributes to WT pathogenesis
by inhibiting MET (Fig. 8C). These results, together
with genetic evidence showing defects in miRNA-
processing genes in WT [8–12], reinforce the critical
role that post-transcriptional gene regulation plays in
WT pathogenesis.
5. Conclusions
Our genome-wide DNA methylation analysis of WT
has identified ESRP2 as a novel differentially methy-
lated gene. ESRP2 was frequently silenced by DNA
hypermethylation in WT, and this occurred early in
WT development (in nephrogenic rests). ESRP2 inhib-
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Fig. 8. ESRP2 action in Wilms tumour. (A) Venn diagram comparing the 728 unique genes identified in this study (SE + MXE + RI, skipped
exons; mutually exclusive exons and retained introns; Fig. 6) with 1663 WT1 DNA-binding targets identified by chromatin
immunoprecipitation in developing kidney [50] and 4503 WT1 RNA-binding targets (protein-coding genes) identified by RNA
immunoprecipitation in M15 mesonephric cells [51]. (B) ESRP2 may be required for epithelial differentiation, to form nephrons during kidney
development. (C) Loss of ESRP2 function by hypermethylation may inhibit normal differentiation and therefore promote persistence of
undifferentiated blastema, leading to nephrogenic rest formation and eventual progression to Wilms tumour. B and C adapted from Fig. 2 in
reference [1].
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suppressed tumour growth of orthotopic xenografts in
nude mice, demonstrating that ESRP2 acts as a
tumour suppressor gene in WT. Using RNA-seq of the
ESRP2-expressing WT cell lines, we have identified
several novel splicing targets, some of which affect
pathways known to be important in kidney develop-
ment. We propose that epigenetic inactivation of
ESRP2 disrupts the regulation of alternative splicing
during the mesenchymal to epithelial transition in
early kidney development, to generate WT.
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